Eagle’s Eye View: ACC Updated Expert Consensus Decision Pathway on HFpEF
In this week’s View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then reviews evidence from the DAPT-MVD trial demonstrating that extended DAPT lowers the risk of cardiovascular events after percutaneous coronary intervention (PCI) in multivessel coronary artery disease. Finally, Dr. Eagle explores ACC’s updated expert consensus decision pathway addressing the management of heart failure preserved ejection fraction (HFpEF).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Atherosclerotic Disease (CAD/PAD), Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Interventions and Coronary Artery Disease, Interventions and Vascular Medicine, Hypertension, Acute Coronary Syndromes, Vascular Medicine
Keywords: Venous Thromboembolism, Pulmonary Embolism, Upper Extremity Deep Vein Thrombosis, Cancer, Atrial Fibrillation, Influenza Vaccines, Primary Prevention, Clopidogrel, Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Renal Insufficiency, Renal Insufficiency, Chronic, Diabetes Mellitus, Adiposity, Edema, Dyspnea, Heart Failure, Hypertension, Cardiomyopathies, Heart Failure, Preserved Ejection Fraction, EaglesEyeView
